Monday, August 24

Browsing: LANPC

Treatments

Carboplatin-Based IC-CCRT Better Tolerated Vs Cisplatin in LA-NPC

By NewsCancerMay 31, 20260

Receipt of carboplatin-based induction-concurrent chemoradiotherapy (IC-CCRT) displayed noninferior efficacy and a lower frequency of toxicities vs cisplatin-based IC-CCRT among patients…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

Browsing: LANPC

Carboplatin-Based IC-CCRT Better Tolerated Vs Cisplatin in LA-NPC

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

<![CDATA[Toward Chemo-Free Regimens – What's Next for DLBCL Treatment]]>

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

<![CDATA[Toward Chemo-Free Regimens – What's Next for DLBCL Treatment]]>

Latest Post

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

Subscribe to Updates

What's Hot

Browsing: LANPC